FilingPulse

ACXP insider filings

Acurx Pharmaceuticals, Inc. — 36 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-04-22. Screen ACXP transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ACXP between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.

Recent insider filings — Acurx Pharmaceuticals, Inc.

FiledFormInsiderReported transactionsSource
2026-04-224Sailer Carl — DirectorGrant/award (A): 2,150 (derivative) @ $0EDGAR
2026-04-224Donohue James J. — DirectorGrant/award (A): 2,150 (derivative) @ $0EDGAR
2026-04-224Shawah Robert G. — Chief Financial OfficerGrant/award (A): 25,900 (derivative) @ $0EDGAR
2026-04-224DEAN JACK H — DirectorGrant/award (A): 2,150 (derivative) @ $0EDGAR
2026-04-224Scodari Joseph C — DirectorGrant/award (A): 2,150 (derivative) @ $0EDGAR
2026-04-224LUCI DAVID P — President and CEO, DirectorGrant/award (A): 37,100 (derivative) @ $0EDGAR
2026-04-224HARRISON THOMAS L — DirectorGrant/award (A): 2,150 (derivative) @ $0EDGAR
2026-04-224DELUCCIA ROBERT J — DirectorGrant/award (A): 37,100 (derivative) @ $0EDGAR
2025-02-064Shawah Robert G. — Chief Financial OfficerGrant/award (A): 145,500 (derivative) @ $0EDGAR
2025-02-064LUCI DAVID P — President and CEO, Director, 10% ownerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-02-064DELUCCIA ROBERT J — Director, 10% ownerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2025-01-084Sailer Carl — DirectorPurchase (P): 24,631 @ $1.01 · Purchase (P): 24,631 (derivative) @ $0EDGAR
2025-01-084Donohue James J. — DirectorPurchase (P): 9,852 @ $1.01 · Purchase (P): 9,852 (derivative) @ $0EDGAR
2025-01-084DEAN JACK H — DirectorPurchase (P): 9,852 @ $1.01 · Purchase (P): 9,852 (derivative) @ $0EDGAR
2025-01-084Scodari Joseph C — DirectorPurchase (P): 24,631 @ $1.01 · Purchase (P): 24,631 (derivative) @ $0EDGAR
2025-01-084LUCI DAVID P — President and CEO, Director, 10% ownerPurchase (P): 49,261 @ $1.01 · Purchase (P): 49,261 (derivative) @ $0EDGAR
2025-01-084DELUCCIA ROBERT J — Director, 10% ownerPurchase (P): 49,261 @ $1.01 · Purchase (P): 49,261 (derivative) @ $0EDGAR
2024-06-184Sailer Carl — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-06-184Donohue James J. — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-06-184DEAN JACK H — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-06-184Scodari Joseph C — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-06-184HARRISON THOMAS L — DirectorGrant/award (A): 12,000 (derivative) @ $0EDGAR
2024-04-034Shawah Robert G. — Chief Financial OfficerGrant/award (A): 145,000 (derivative) @ $0EDGAR
2024-04-034LUCI DAVID P — President and CEO, Director, 10% ownerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-04-034DELUCCIA ROBERT J — Director, 10% ownerGrant/award (A): 250,000 (derivative) @ $0EDGAR
2024-01-224Sailer Carl — DirectorOption exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0EDGAR
2024-01-044LUCI DAVID P — President and CEO, Director, 10% ownerOption exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0EDGAR
2024-01-044DELUCCIA ROBERT J — Director, 10% ownerGift (G): 40,000 @ $0 · Gift (G): 40,000 @ $0 · Gift (G): 30,000 @ $0 · Option exercise (M): 19,737 @ $3.55 · Option exercise (M): 19,737 (derivative) @ $0EDGAR
2023-06-164Donohue James J. — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2023-06-164Sailer Carl — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2023-06-164DEAN JACK H — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2023-06-164Scodari Joseph C — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2023-06-164HARRISON THOMAS L — DirectorGrant/award (A): 10,000 (derivative) @ $0EDGAR
2023-02-244Shawah Robert G. — Chief Financial OfficerGrant/award (A): 75,000 (derivative) @ $0EDGAR
2023-02-244LUCI DAVID P — President and CEO, Director, 10% ownerGrant/award (A): 130,000 (derivative) @ $0EDGAR
2023-02-244DELUCCIA ROBERT J — Director, 10% ownerGrant/award (A): 130,000 (derivative) @ $0EDGAR

Recent 8-K events — Acurx Pharmaceuticals, Inc.

FiledFormItems reportedSource
2026-04-168-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-09-228-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits		EDGAR
2025-09-198-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-07-318-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-07-178-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2025-06-208-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-05-138-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-05-088-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits		EDGAR
2025-03-288-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR

Registration filings — Acurx Pharmaceuticals, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ACXP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →